Statins for primary prevention in people with a 10% 10-year cardiovascular risk: too much medicine too soon?

about

Statins for primary prevention in people with a 10% 10-year cardiovascular risk: too much medicine too soon?

Item

http://www.wikidata.org/entity/Q50223334

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Statins for primary prevention ...... k: too much medicine too soon?

@en

Statins for primary prevention ...... k: too much medicine too soon?

@nl

type

Item

label

Statins for primary prevention ...... k: too much medicine too soon?

@en

Statins for primary prevention ...... k: too much medicine too soon?

@nl

prefLabel

Statins for primary prevention ...... k: too much medicine too soon?

@en

Statins for primary prevention ...... k: too much medicine too soon?

@nl

P1476

Statins for primary prevention ...... k: too much medicine too soon?

@en

P2093

Dharani Yerrakalva

http://www.w3.org/2001/XMLSchema#string

Simon J Griffin

http://www.w3.org/2001/XMLSchema#string

P2860

Statins for the primary prevention of cardiovascular disease

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice.

Helping patients decide: ten steps to better risk communication.

Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk.

Statin tolerability: In defence of placebo-controlled trials.

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.

P304

40-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3399/BJGP17X688789

http://www.w3.org/2001/XMLSchema#string

P433

654

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28034950

http://www.w3.org/2001/XMLSchema#string

P932

5198615

http://www.w3.org/2001/XMLSchema#string